Financing supports advancement of AHB-137 toward potential commercialization, including its Phase 3 registrational program and commercialization readiness

融资支持推进AHB-137的潜在商业化进程，包括其III期注册临床试验项目及商业化准备工作

Proceeds will also accelerate AHB-171 and next-generation combination approaches designed to advance functional cure for chronic hepatitis B

所得资金还将加速推进AHB-171以及旨在推动慢性乙型肝炎功能性治愈的下一代联合疗法

Series C brings AusperBio's total capital raised to $360 million since 2024

C轮融资使AusperBio自2024年以来的融资总额达到3.6亿美元

SAN FRANCISCO

旧金山

,

，

Aug. 27, 2026

2026年8月27日

/PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively 'AusperBio' or the 'Company'), a near-commercial biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B (CHB) and other diseases, today announced the closing of its .

/PRNewswire/ -- AusperBio Therapeutics, Inc. 与 Ausper Biopharma Co., Ltd.（合称“AusperBio”或“公司”）是一家接近商业化阶段的生物制药公司，专注于开发用于治疗慢性乙型肝炎（CHB）及其他疾病的靶向寡核苷酸疗法。该公司今日宣布完成其

$120 million Series C financing

1.2亿美元C轮融资

.

。

The financing was led by a leading strategic investor, with participation from new investor

本轮融资由一家领先的战略投资者领投，并有新投资者参与。

RA Capital Management, L.P. ('RA Capital')

RA Capital Management, L.P.（“RA Capital”）

, alongside continued support from AusperBio's existing investors, including

，以及来自AusperBio现有投资者（包括

HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments

汉康资本、Sherpa Capital、InnoPinnacle Fund、启明创投、源生创投和鼎晖投资

. With the completion of the Series C, AusperBio has raised $360 million since 2024, reflecting strong and sustained investor confidence in the potential of the Company's lead programs and differentiated oligonucleotide platforms.

随着C轮融资的完成，AusperBio自2024年以来已筹集3.6亿美元，这反映出投资者对公司领先项目及其差异化寡核苷酸平台潜力的强烈且持续的信心。

The financing will support the continued development of

这笔融资将支持持续开发

AHB-137

AHB-137

, AusperBio's lead investigational ASO therapy for CHB, including its

，AusperBio 公司针对慢性乙型肝炎（CHB）的主要在研反义寡核苷酸（ASO）疗法，包括其

Phase 3 registrational program and commercialization readiness

III期注册临床试验项目及商业化准备就绪

. Proceeds will also accelerate the development of

. 所得款项还将加速推进

AHB-171

AHB-171

, the Company's investigational HBV siRNA candidate built on its proprietary

，该公司基于其专有技术开发的在研乙型肝炎病毒（HBV）小干扰RNA（siRNA）候选药物

Au-HALO™ targeted delivery platform

Au-HALO™ 靶向递送平台

, advance next-generation combination approaches for CHB, and further expand the Company's pipeline of targeted oligonucleotide therapeutics addressing significant unmet medical needs.

，推进针对慢性乙型肝炎（CHB）的下一代联合疗法，并进一步拓展公司靶向寡核苷酸治疗产品的管线，以满足重大的未竟医疗需求。

'This financing represents an important inflection point for AusperBio as we advance AHB-137 toward potential commercialization while developing next-generation therapies for CHB,' said

“这笔融资标志着AusperBio的一个重要转折点，我们在推进AHB-137潜在商业化的同时，也在开发针对慢性乙型肝炎（CHB）的下一代疗法。”

Dr. Guofeng Cheng, co-founder and CEO of AusperBio

郭成峰博士，AusperBio 联合创始人兼首席执行官

. 'We are grateful for the continued confidence of our existing investors and pleased to welcome RA Capital to AusperBio. We look forward to building on this momentum to advance our strategy toward functional cure and unlock new opportunities across our oligonucleotide platforms.'

“我们感谢现有投资者的持续信任，并很高兴欢迎RA Capital加入AusperBio。我们期待借助这一势头，推进实现功能性治愈的战略，并在我们的寡核苷酸平台中开拓新的机会。”

Dr. Chris Yang, co-founder and CSO of AusperBio

AusperBio 联合创始人兼首席科学官 Chris Yang 博士

, added, 'AHB-137 has demonstrated promising clinical activity in patients and has the potential to serve as a backbone therapy for functional cure of CHB. Our Med-Oligo™ ASO, Au-HALO™ targeted delivery and siRNA discovery platforms enable complementary approaches designed to achieve deeper and more durable antiviral responses.

，并补充道：“AHB-137 在患者中已展现出令人鼓舞的临床活性，有望成为实现慢性乙型肝炎（CHB）功能性治愈的基础疗法。我们的 Med-Oligo™ 反义寡核苷酸（ASO）、Au-HALO™ 靶向递送以及 siRNA 发现平台，能够提供互补的技术路径，旨在实现更深层次且更持久的抗病毒反应。”

This financing will enable us to further advance these platforms and build on their potential to generate differentiated targeted oligonucleotide therapies for CHB and other diseases with significant unmet medical needs.'.

此次融资将使我们能够进一步推进这些平台，并挖掘其潜力，开发针对慢性乙型肝炎（CHB）及其他存在重大未满足医疗需求疾病的差异化靶向寡核苷酸疗法。

About AHB-137

关于AHB-137

AHB-137 is AusperBio's lead investigational unconjugated antisense oligonucleotide (

AHB-137 是 AusperBio 公司领先的在研非共轭反义寡核苷酸（

ASO

应用商店优化

) therapy for chronic hepatitis B (CHB), developed using the Company's proprietary

）用于慢性乙型肝炎（CHB）的治疗，采用公司专有技术开发

Med-Oligo™ ASO

Med-Oligo™ 反义寡核苷酸

platform

平台

. AHB-137 is designed to suppress hepatitis B surface antigen (HBsAg) production, inhibit viral DNA replication, and promote immune reactivation, with the goal of achieving a functional cure for CHB. AHB-137 has demonstrated promising clinical results and is currently being evaluated in a

AHB-137 旨在抑制乙型肝炎表面抗原（HBsAg）的产生，抑制病毒 DNA 复制，并促进免疫再激活，以期实现慢性乙型肝炎（CHB）的功能性治愈。AHB-137 已展现出令人鼓舞的临床结果，目前正在一项

Phase 3 trial in China

中国三期临床试验

, following completion of a global Phase 1 study and multiple Phase 2 studies. The Company is advancing AHB-137 through a coordinated global development strategy toward potential commercialization. AHB-137 is an investigational product candidate and has not been approved by any regulatory authority..

，在完成一项全球性1期临床试验和多项2期临床试验之后。本公司正通过协调一致的全球开发策略推进AHB-137的研发，以期实现潜在的商业化。AHB-137是一款在研候选产品，尚未获得任何监管机构的批准。

About AHB-171

关于 AHB-171

AHB-171 is an investigational hepatocyte-targeted

AHB-171 是一种在研的肝细胞靶向

siRNA

小干扰RNA

therapeutic candidate for the treatment of CHB that leverages AusperBio's proprietary

一种利用AusperBio专有技术治疗慢性乙型肝炎（CHB）的候选药物

Au-HALO™

Au-HALO™

liver-targeting delivery platform

肝靶向递送平台

. AHB-171 is designed to selectively suppress viral gene expression and provide potent and sustained antiviral activity. As the first clinical candidate developed using the

AHB-171 旨在选择性抑制病毒基因表达，并提供强效且持久的抗病毒活性。作为首个利用

Au-HALO™

Au-HALO™

platform

平台

, AHB-171 is advancing the clinical validation of the Company's targeted delivery and siRNA capabilities and broadening the Company's differentiated HBV pipeline. AHB-171 is an investigational product candidate and has not been approved by any regulatory authority.

AHB-171 正在推进公司靶向递送和 siRNA 技术的临床验证，并拓宽公司差异化的乙型肝炎病毒（HBV）产品管线。AHB-171 是一种研究性候选产品，尚未获得任何监管机构的批准。

About Chronic Hepatitis B

关于慢性乙型肝炎

Chronic hepatitis B remains a significant global health burden, affecting an estimated 254 million people worldwide and causing approximately 1.1 million deaths annually, primarily from cirrhosis and liver cancer, according to the World Health Organization. Current therapies can suppress viral replication but rarely achieve a functional cure, leaving many patients requiring long-term treatment..

据世界卫生组织称，慢性乙型肝炎仍然是全球重大的健康负担，全球估计有2.54亿人受其影响，每年导致约110万人死亡，死因主要为肝硬化和肝癌。目前的疗法可以抑制病毒复制，但很少能实现功能性治愈，导致许多患者需要长期治疗。

About AusperBio

关于 AusperBio

AusperBio is a near-commercial biopharmaceutical company focused on developing differentiated oligonucleotide therapeutics and targeted delivery technologies, with an initial focus on achieving a functional cure for chronic hepatitis B. The Company's innovation engine is built on its proprietary

AusperBio 是一家接近商业化阶段的生物制药公司，专注于开发具有差异化的寡核苷酸疗法和靶向递送技术，初期重点在于实现慢性乙型肝炎的功能性治愈。该公司的创新引擎基于其专有

Med-Oligo™ ASO

Med-Oligo™ 反义寡核苷酸

and

和

Au-HALO™

Au-HALO™

targeted delivery platforms

靶向递送平台

, supporting the development of therapies across multiple oligonucleotide modalities. With multiple clinical-stage programs and a growing pipeline, AusperBio is advancing a backbone-based combination strategy for functional cure of CHB while exploring opportunities in additional disease areas with significant unmet medical needs.

，支持多种寡核苷酸疗法形式的开发。凭借多项处于临床阶段的项目和不断扩大的研发管线，AusperBio 正在推进一种基于骨架的联合策略，以实现慢性乙型肝炎（CHB）的功能性治愈，同时探索在其他存在重大未满足医疗需求的疾病领域的机会。

For more information, visit .

更多信息，请访问。

www.ausperbio.com

www.ausperbio.com

Forward-Looking Statements

前瞻性陈述

This press release is prepared by AusperBio (the 'Company', 'We') for informational purposes only. Forward-looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as 'anticipate', 'expect', 'intend', 'plan', 'believe', 'continue', 'could', 'potential', 'may', 'will', 'goal' or similar expressions and the negatives of those terms.

本新闻稿由AusperBio（“公司”、“我们”）编制，仅供信息参考。前瞻性陈述包括所有非历史事实的陈述，在某些情况下，可以通过“预期”、“预计”、“打算”、“计划”、“相信”、“继续”、“能够”、“潜在”、“可能”、“将”、“目标”或类似表述以及这些术语的否定形式来识别。

However, not all forward-looking statements contain these identifying words..

然而，并非所有前瞻性陈述都包含这些识别性词语。

These forward-looking statements involve substantial known and unknown risks and uncertainties, including the risk that results in earlier clinical studies may not be indicative of future results and that any product candidates may not ultimately obtain required approvals or meaningfully improve patient outcomes, and other factors that are beyond the Company's control and are difficult to predict and may cause our actual results, timing of results, or achievements to be materially different from the information expressed or implied by these forward-looking statements.

这些前瞻性陈述涉及大量已知和未知的风险与不确定性，包括早期临床研究结果可能无法预示未来结果的风险，以及任何候选产品最终可能无法获得必要的批准或显著改善患者预后的风险；此外，还包括其他超出公司控制范围、难以预测的因素，这些因素可能导致我们的实际结果、结果出现的时间或成就与这些前瞻性陈述所表达或暗示的信息存在重大差异。

We anticipate that subsequent events and developments may cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law..

我们预计，后续事件和发展可能导致我们的预期和假设发生变化，除法律要求外，我们不承担因新信息、未来事件或其他原因而更新或修订任何前瞻性陈述的义务。

Except as expressly required by law, the Company and/or its officers, directors, employees, and agents shall not assume responsibility for the accuracy and completeness of the forward-looking statements in the information provided.

除非法律明确要求，公司及其高级职员、董事、员工和代理人不对所提供信息中的前瞻性陈述的准确性和完整性承担责任。

Media Contact

媒体联系人

Email:

电子邮件：

[email protected]

[email protected]

Investor Contact

投资者联系

Tel: 650-888-1756 (US)

电话：650-888-1756（美国）

Email:

电子邮件：

[email protected]

[email protected]

SOURCE AusperBio Therapeutics Inc.

来源：AusperBio Therapeutics Inc.

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示